Adavosertib is under clinical development by AstraZeneca and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Adavosertib’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 27 Jun 2022 decreased Adavosertib’s LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Adavosertib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Adavosertib overview

Adavosertib (AZD-1775, MK-1775) is under development for the treatment of advanced refractory lymphoma and multiple myeloma, advanced solid tumors including head and neck squamous cell carcinoma, advanced and metastatic pancreatic adenocarcinoma, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer, oral cancer, cervical cancer, vaginal cancer, recurrent endometrial cancer, metastatic triple negative breast cancer(as a second and third line therapy), relapsed and refractory acute myeloid leukemia, myelodysplastic syndrome,definitive chemoradiation esophageal and gastroesophageal junction cancer, small-cell lung cancer and platinum-resistant TP53-mutated fallopian tube and primary peritoneal cancer, metastatic colorectal cancer and adenocarcinoma of the pancreatic cancer. It is a small molecule administered orally in the form of capsule. It acts by targeting Wee1. It was also under development for the treatment of non-squamous non-small-cell lung cancer. The drug candidate is a new molecular entity (NME).

It was under development for head and neck cancer, esophageal cancer and gastric cancer, epithelial ovarian, uterine cancer and solid tumors.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View Adavosertib LOA Data

Report Segments
  • Innovator
Drug Name
  • Adavosertib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.